Last reviewed · How we verify
CT-P59
CT-P59 is a COVID-19 treatment that works by binding to the SARS-CoV-2 spike protein.
CT-P59 is a COVID-19 treatment that works by binding to the SARS-CoV-2 spike protein. Used for Treatment of COVID-19.
At a glance
| Generic name | CT-P59 |
|---|---|
| Also known as | regdanvimab |
| Sponsor | Celltrion |
| Drug class | monoclonal antibody |
| Target | SARS-CoV-2 spike protein |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
CT-P59 is a monoclonal antibody that targets the SARS-CoV-2 spike protein, preventing the virus from entering host cells. This mechanism of action is similar to other COVID-19 treatments that target the spike protein.
Approved indications
- Treatment of COVID-19
Common side effects
- Injection site reactions
- Fatigue
- Headache
Key clinical trials
- A Phase 2/3 Study to Evaluate the Efficacy and Safety of CT-P59 in Patients With Mild to Moderate SARS-CoV-2 Infection (PHASE2, PHASE3)
- This is a Phase 1 Study to Evaluate the Safety,Tolerability and Virology of CT P59 in Patients With Mild Symptoms of Symptoms of Coronavirus Disease (COVID-19) (PHASE1)
- To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P59 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CT-P59 CI brief — competitive landscape report
- CT-P59 updates RSS · CI watch RSS
- Celltrion portfolio CI